HAIKOU CITY, China, July 6
/PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE
AMEX: CPHI) ("China Pharma" or the "Company"), a leading
fully-integrated specialty pharmaceutical company in China, today announced that the Company's
Chief Financial Officer, Mr. Frank
Waung, has been invited by Global Hunter Securities to
present at the Global Hunter Securities ("GHS") China
Conference.
The GHS China Conference will be held on July 11 - 13, 2010 at the St. Regis Hotel in
San Francisco. Mr. Frank Waung is scheduled to make a presentation
at 3 P.M. PT on Monday, July 12, 2010 and will be available to
meet with investors throughout the conference.
For further details, please contact your respective
institutional sales representative.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty
pharmaceutical company that develops, manufactures and markets a
diversified portfolio of products focused on conditions with a high
incidence and high mortality rates in China, including cardiovascular, CNS,
infectious, and digestive diseases. The Company's cost-effective,
high margin business model is driven by market demand and supported
by eight scalable GMP-certified product lines covering the major
dosage forms. In addition, the Company has a broad and expanding
nationwide distribution network across 30 provinces, municipalities
and autonomous regions. The Company's wholly owned subsidiary,
Hainan Helpson Medical & Biotechnology Co., Ltd., is located in
Haikou City, Hainan Province. For more information about
China Pharma Holdings, Inc., please visit
http://www.chinapharmaholdings.com
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements, which may include, but are not
limited to, such factors as success of new product development,
unanticipated changes in product demand, increased competition,
downturns in the Chinese economy, uncompetitive levels of research
and development, and other information detailed from time to time
in the Company's filings and future filings with the United States
Securities and Exchange Commission. The forward-looking statements
made herein speak only as of the date of this press release and the
Company undertakes no duty to update any forward-looking statement
to conform the statement to actual results or changes in the
company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
Tel: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
CCG Investor Relations
Vivian Chen, Sr. Market Intelligence Exec.
Tel: +1-646-701-7445 (New York)
Email: vivian.chen@ccgir.com
SOURCE China Pharma Holdings, Inc.